Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).

被引：0
|
作者：
Zinner, R
Govindan, R
Wozniak, AJ
Wade, JL
Belani, CP
Thienelt, CD
Hensing, TA
Reiling, RB
Natale, RB
Wiznitzer, I
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Washington, Sch Med, St Louis, MO USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Decatur Mem Hosp, Decatur, IL USA
[5] UPMC, Pittsburgh, PA USA
[6] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[7] Evanston NW Healthcare, Evanston, IL USA
[8] Presbyterian Canc Ctr, Charlotte, NC USA
[9] Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA
[10] Lynn Reg Canc Ctr W, Boca Raton, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7082
引用
收藏
页码：636S / 636S
页数：1
相关论文
共 50 条
  • [21] Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
    Chang, GC
    Chen, KC
    Yang, TY
    Yin, MC
    Lin, CP
    Kuo, BIT
    Hsu, JY
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (01) : 73 - 77
  • [22] Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
    Gee-Chen Chang
    Kun-Chieh Chen
    Tsung-Ying Yang
    Ming-Chang Yin
    Ching-Pei Lin
    Benjamin Ing-Tiau Kuo
    Jeng-Yuan Hsu
    Investigational New Drugs, 2005, 23 : 73 - 77
  • [23] Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
    Satouchi, M.
    Negoro, S.
    Funada, Y.
    Urata, Y.
    Shimada, T.
    Yoshimura, S.
    Kotani, Y.
    Sakuma, T.
    Watanabe, H.
    Adachi, S.
    Takada, Y.
    Yatabe, Y.
    Mitsudomi, T.
    BRITISH JOURNAL OF CANCER, 2007, 96 (08) : 1191 - 1196
  • [24] Gefitinib for patients with advanced NSCLC treated on the expanded access programme: A institution experience
    Cruz, M
    Katz, A
    Simon, S
    Tabacof, J
    Gansl, R
    Smaletz, O
    LUNG CANCER, 2005, 49 : S389 - S390
  • [25] Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
    M Satouchi
    S Negoro
    Y Funada
    Y Urata
    T Shimada
    S Yoshimura
    Y Kotani
    T Sakuma
    H Watanabe
    S Adachi
    Y Takada
    Y Yatabe
    T Mitsudomi
    British Journal of Cancer, 2007, 96 : 1191 - 1196
  • [26] Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
    Longarini, Raffaella
    Buti, Sebastiano
    Bosio, Giancarlo
    Brighenti, Matteo
    Porzio, Rosa
    Negri, Federica
    Passalacqua, Rodolfo
    ANNALS OF ONCOLOGY, 2007, 18 : 30 - 30
  • [27] Initial safety results of an expanded access program (EAP) of erlotinib in non-small cell lung cancer (NSCLC).
    Reck, M.
    Perng, R.
    Groen, H.
    Riska, H.
    Pirker, R.
    Sederholm, C.
    Caspar, C.
    Boyer, M.
    Berzinec, P.
    Allan, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 411S - 411S
  • [28] Gefitinib (ZD1839) as compassionate use therapy in patients (pts) with advanced non-small-cell lung cancer (NSCLC) after failing prior chemotherapy
    Genestreti, G.
    Giovannini, M.
    Fiorio, E.
    Colaluca, P.
    Cipriani, A.
    Palazzi, M.
    Salmaso, F.
    Cartei, G.
    Cetto, G. L.
    Santo, A.
    ANNALS OF ONCOLOGY, 2005, 16 : 26 - 27
  • [29] Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland
    Knetki-Wroblewska, M.
    Kowalski, D. M.
    Pluzanski, A.
    Stanowska, O.
    Wisniewski, P.
    Winiarczyk, K.
    Zaborowska-Szmit, M.
    Zajda, K.
    Prochorec-Sobieszek, M.
    Krzakowski, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S641 - S641
  • [30] An expanded access clinical program of erlotinib in patients (pts) with advanced stage IIIb/IV non-small-cell lung cancer (NSCLC) - an update of a single institution experience
    Tawas, M.
    Gauler, T.
    Schuett, P.
    Sailer, V.
    Bildat, S.
    Korfee, S.
    Seeber, S.
    Eberhardt, W. E. E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 390 - 390
12345